Generic Olumiant Availability
Last updated on Jul 9, 2025.
Olumiant is a brand name of baricitinib, approved by the FDA in the following formulation(s):
OLUMIANT (baricitinib - tablet;oral)
-
Manufacturer: ELI LILLY AND CO
Approval date: May 31, 2018
Strength(s): 2MG [RLD] [AB] -
Manufacturer: ELI LILLY AND CO
Approval date: October 8, 2019
Strength(s): 1MG [RLD] [AB] -
Manufacturer: ELI LILLY AND CO
Approval date: May 10, 2022
Strength(s): 4MG [RLD] [AB]
Is there a generic version of Olumiant available?
No. There is currently no therapeutically equivalent version of Olumiant available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Olumiant. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections
Patent 11,045,474
Issued: June 29, 2021
Inventor(s): Gavegnano; Christina et al.
Assignee(s): Emory University (Atlanta, GA); The United States Government as Repersentative by the Department of Veterans Affairs (Washington, DC)Compounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.
Patent expiration dates:
- November 30, 2032✓
- November 30, 2032
-
Methods for treating hair loss disorders
Patent 11,806,555
Issued: November 7, 2023
Inventor(s): Christiano; Angela M. et al.
Assignee(s): The Trustees of Columbia University in the City of New York (New York, NY)The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
Patent expiration dates:
- November 2, 2031✓
- November 2, 2031
-
Azetidine and cyclobutane derivatives as JAK inhibitors
Patent 8,158,616
Issued: April 17, 2012
Inventor(s): Rodgers James D. & Shepard Stacey
Assignee(s): Incyte CorporationThe present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
Patent expiration dates:
- May 31, 2032✓✓
- May 31, 2032
-
Azetidine and cyclobutane derivatives as JAK inhibitors
Patent 8,420,629
Issued: April 16, 2013
Inventor(s): Rodgers James D. & Shepard Stacey
Assignee(s): Incyte CorporationThe present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.
Patent expiration dates:
- March 10, 2029✓
- March 10, 2029
-
Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
Patent 9,089,574
Issued: July 28, 2015
Inventor(s): Gavegnano Christina & Schinazi Raymond F.
Assignee(s): EMORY UNIVERSITYCompounds, compositions, and methods of treatment and prevention of HIV infection are disclosed. The compounds are pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidine JAK inhibitors. Combinations of these JAK inhibitors and additional antiretroviral compounds, such as NRTI, NNRTI, integrase inhibitors, entry inhibitors, protease inhibitors, and the like, are also disclosed. In one embodiment, the combinations include a combination of adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, optionally in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.
Patent expiration dates:
- November 30, 2032✓
- November 30, 2032
-
Methods for treating hair loss disorders
Patent 9,737,469
Issued: August 22, 2017
Inventor(s): Christiano Angela M. & Clynes Raphael
Assignee(s): The Trustees of Columbia University in the City of New YorkThe invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.
Patent expiration dates:
- November 2, 2031✓
- November 2, 2031
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- May 10, 2025 - TREATMENT OF COVID-19 IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NONINVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
- June 13, 2025 - TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA
More about Olumiant (baricitinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (15)
- Drug images
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antirheumatics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
| AB | Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
